2026-8-31 (Mon)

Business NVIDIA Corporation is a data center-scale AI infrastructure and accelerated-computing company, listed on NASDAQ since January 1999. It operates two principal segments - Compute & Networking (data center accelerated computing, networking platforms, AI software, automotive platforms) and Graphics (GeForce/RTX GPUs for gaming and PCs). With a market cap around $5.33 trillion, it is the dominant supplier of AI accelerators to hyperscalers and cloud providers.

Today’s take On Monday Aug 31, 2026, NVDA rose +1.48% (+$3.23) to close at $220.78, following its announcement of a $3.5 billion investment in Taiwan-based MediaTek via convertible bonds. The deal deepens a partnership spanning AI infrastructure, local/PC AI computing, and automotive, with MediaTek adopting NVIDIA's NVLink Fusion interconnect platform to let custom XPU customers plug into NVIDIA's rack-scale AI factories. The move extends an ongoing post-earnings story: on Aug 26 NVDA reported Q2 FY27 revenue of $96.2B (up ~120% YoY) and beat-and-raised, then pulled back -4.57% to $217.55 on Aug 28 on margin concerns and Fed Chair Walsh's hawkish remarks. Analyst price-target lifts (Morgan Stanley to $300, Raymond James to a Street-high $515) and Cathie Wood's ARK Invest adding ~$55.6M on Aug 28 reinforced buying. Monday's gain also represents mean-reversion from Friday's elevated-bar pullback.

Business CNH Industrial N.V. (NYSE: CNH) is a global capital goods company headquartered in Basildon, UK, legally incorporated in the Netherlands. It designs, manufactures, and finances agricultural and construction equipment under brands including Case IH, New Holland, STEYR, and Raven, operating across North America, Europe, South America, and Asia-Pacific.

Today’s take On August 31, 2026, Baird upgraded CNH Industrial from Neutral to Outperform with a price target of $15.00 (up from $11.00, ~+28% implied upside), citing a margin recovery outlook as tariff cost drag lessens into 2027. The stock gapped up ~3.7% at open ($12.11 vs. $11.68 prior close), traded up to $12.25, and closed at $11.83 (+1.28%). Baird also upgraded four agriculture names (Titan Machinery, Deere, AGCO) on improving farm fundamentals. Adding to the catalyst, CNH announced a strategic alliance with Bourgault Industries the same day to expand its global seeding portfolio, with Bourgault manufacturing co-branded Case IH and New Holland equipment distributed through CNH's dealer network in North America and Australia. The stock had already rallied ~18% over the prior two weeks (from $10.03 on Aug 18) following a Q2 earnings beat (adjusted EPS $0.13 vs. $0.11 consensus) and raised FY2026 guidance reported on Aug 3.

Business Nu Holdings Ltd. (NYSE: NU) is a Cayman Islands-incorporated, São Paulo-headquartered digital banking and fintech group, best known for its flagship brand Nubank, the largest digital bank in Latin America. It operates across Brazil, Mexico, Colombia, the Cayman Islands, and the United States, offering credit and prepaid cards, digital checking/savings (NuAccount), mobile payments, investments, insurance, and the premium Ultraviolet metal card. As of Q2 2026 it served ~138.9 million customers and trades as a Class A NYSE listing (IPO Dec 2021).

Today’s take On 2026-08-31, NU closed at $14.55, +$0.25 (+1.75%), within a $14.21-$14.64 range after opening at $14.35. The session was essentially a post-selloff rebound: the prior session (Fri Aug 28) NU fell 3.9% to $14.30 despite record Q2 net income, blamed on a rising 90+ day NPL ratio (6.9% vs 6.5%). On Aug 31, dip-buyers anchored on the bullish setup — a consensus Buy from 22 analysts with an average price target of $18.78 (~31% upside from the prior close). This extended momentum from the Aug 13 blowout Q2 report (first-ever $1B+ quarterly net income at $1.06B, +49% YoY FX-neutral; revenue $5.88B, +39%; 138.9M customers; ARPAC $17.10; ROE 33%), which had triggered a wave of hikes (Needham→$19, UBS→$18.20, Morgan Stanley $21, Susquehanna→$16, CICC→$19). The stock remained ~24% below its $18.98 52-week high, offering technical room for a bounce despite lingering credit-quality concerns.

Business American Airlines Group Inc. (NASDAQ: AAL), headquartered in Fort Worth, Texas, is one of the world's largest network air carriers, operating scheduled passenger and cargo air transportation across Domestic, Latin America, Atlantic, and Pacific segments. The company is highly sensitive to jet fuel costs, its largest variable expense, making it structurally vulnerable to crude-oil price spikes.

Today’s take AAL fell -1.54% to $13.43 on Aug 31, 2026, the primary driver being an escalation in U.S.-Iran military tensions near the Strait of Hormuz, which pushed crude oil up more than 3% above $86/bbl. Rising jet fuel directly compresses airline margins; AAL slid faster than the Nasdaq (-0.53%), S&P 500 (-0.49%), and the broader Industrials sector (-1%). The macro shock compounded existing company-specific overhangs: Q2 2026 fuel expense surged 83.3% YoY to $4.88B, FY2026 EPS guidance was slashed to roughly breakeven (a loss of $0.65 to a profit of $0.65), capacity guidance was trimmed (Q3 now up 3-5% vs. original plan), and a recently rejected merger proposal leaves the carrier executing a turnaround independently. Airlines for America CEO noted carriers are 'eating the cost' of expensive jet fuel rather than fully passing it to consumers.

Business Intel Corporation (NASDAQ: INTC) is a global semiconductor leader headquartered in Santa Clara, California. Founded in 1968 and the pioneer of the x86 architecture, Intel designs and manufactures computing products across two primary operating segments: Intel Products — comprising the Client Computing and Physical AI Group (CCPG) and the Data Center and AI (DCAI) segment — and Intel Foundry, its contract chip-manufacturing business. As of the August 31, 2026 session, Intel had a market capitalization of approximately $470 billion with 5.25 billion shares outstanding. The company delivered record fiscal Q2 2026 revenue of $16.1 billion (up 25% year-over-year), its strongest growth in over fifteen years, with non-GAAP EPS of $0.42. DCAI revenue surged 59% YoY to $6.3 billion, while Intel Fou

Today’s take Intel stock closed at $89.51 on Monday, August 31, 2026, essentially flat (+0.04%, +$0.04) despite a meaningful premarket surge. The session opened at $90.00 and touched an intraday high of $91.85 before fading to a low of $88.97 and closing at $89.51. The primary catalyst was a Sunday-evening report from South Korea's Herald Economy (published Monday morning) that SK Hynix, the world's leading HBM memory maker, is considering Intel Foundry as a second supplier for the base dies (logic dies) used in its next-generation HBM4E high-bandwidth memory. This would break TSMC's monopoly on HBM base-die production, which began with HBM4. The report gave INTC a ~1.5-1.7% premarket boost. However, the stock faded substantially during regular trading as two factors tempered enthusiasm: (1) SK Hynix issued a carefully worded denial stating that 'some content is not consistent with the facts' and that it could not confirm its technology roadmap details, and (2) the report explicitly stated the plan was 'under consideration' rather than a signed agreement, prompting a classic 'buy the rumor, sell the news' dynamic. The broader semiconductor sector was also choppy as investors processed AI-demand

Business Space Exploration Technologies Corp. (SpaceX), listed on Nasdaq as SPCX on June 12, 2026 in the largest IPO in history (~$75B raised at ~$1.77T valuation). The company operates space launch (Falcon/Starship), satellite connectivity (Starlink), and AI compute infrastructure (Grok, rented compute to Anthropic/Google).

Today’s take On 2026-08-31, Fubon Securities initiated coverage on SpaceX (SPCX) with a 'Buy' rating and $183 target price, published via MT Newswires at 17:47 CST (3:12 PM session). This was the day's primary same-session catalyst. The stock opened at $140.03 (down from prior close $141.50), dipped to $139.88, then rallied to a $144.13 high before closing at $143.69, +1.55% (+$2.19). The recovery tracked the Fubon initiation. A supplementary catalyst was Elon Musk's Saturday/Sunday comments (published Aug 31, 2:52 AM) that SpaceX in-house casting can accelerate natural gas turbines by up to 18 months — a 'profound game-changer' for AI power — with SpaceX and Tesla each targeting 100GW/year solar. Benzinga noted shares were down 0.73% overnight to $140.46 on that news before reversing on the analyst initiation. Street consensus mean target is $226.26 (overweight).

Business Tesla, Inc. (NASDAQ: TSLA) designs, manufactures, and sells electric vehicles (Model S/X/3/Y, Cybertruck, and the upcoming Cybercab) as well as energy generation and storage products (Powerwall, Megapack, solar). The company also operates robotaxi (autonomous ride-hailing) services in Austin and Nevada and develops full self-driving (FSD) software, Optimus humanoid robotics, and AI/energy infrastructure tied to data-center power demand.

Today’s take Tesla closed at $367.95, up 5.51% (+$19.22) on Aug. 31, 2026, the largest percent gain since Aug. 21, reaching a one-month high while the S&P 500 fell 0.33% and the Nasdaq dropped 0.12%. The dominant catalyst was investor anticipation of the invite-only Cybercab launch event scheduled for Sept. 3 at Gigafactory Texas, billed as exclusive access to the steering-wheel- and pedal-free two-seater. Nasdaq explicitly framed the gain as driven by 'the upcoming Sept. 3 Cybercab event and renewed interest in FSD and robotaxi plans.' A secondary tailwind: Nevada regulators (NTA) on Aug. 20 approved Tesla's full Autonomous Vehicle Network Company permit, clearing up to 5,000 paid robotaxis across Clark County — roughly a 500x expansion from the earlier 10-vehicle interim cap. A thematic boost came from Elon Musk's weekend X posts on SpaceX in-house natural-gas turbine casting (to accelerate data-center power by up to 18 months), reinforcing Tesla's AI/energy appeal. Tesla was the best performer in the S&P 500 and Nasdaq 100 intraday, a stock-specific rotation into large-cap AI/growth names on a down tape.

Business UiPath, Inc. (NYSE: PATH) is a global leader in agentic automation and robotic process automation (RPA). Its UiPath Platform enables AI agents and software robots to discover, automate, orchestrate, and govern enterprise business processes across financial services, healthcare, manufacturing, retail, and public sector verticals. Founded by Daniel Dines, the company trades as Class A shares on the NYSE.

Today’s take UiPath closed at $18.67 on August 31, 2026, up +$0.52 (+2.87%), driven primarily by a same-day UBS price-target hike. UBS analyst Radi Sultan raised the target to $19.00 from $12.00 (a ~58% increase) while reiterating a Neutral rating, citing recent channel checks pointing to stable demand. The note was explicitly framed ahead of UiPath's Q2 FY2027 earnings, scheduled for September 3 after market close, followed by an Investor Day on September 22. This was not an isolated event: the stock had already rallied ~39% over the prior month from the low-$13s in mid-July, aided by a first-ever GAAP-profitable Q1, the agentic-AI narrative, a large Banco Azteca/Maestro deployment (~8,800 processes, 300+ automations), and prior street target raises (RBC to $15 on 8/14). Q1 ARR reached $1.901B (~12% growth) with net retention of 109%; Q2 ARR guidance was $1.929–$1.934B. Heavy short interest (~29% of float, ~118M shares) may have amplified the positive move as traders trimmed shorts ahead of the binary earnings event.

Business Ambev S.A. is the largest brewer in Latin America and the Caribbean and the regional subsidiary of Anheuser-Busch InBev (62% control), listed on the NYSE as an ADR (NYSE: ABEV; primary B3 listing ABEV3, São Paulo). It produces, distributes, and sells beer (Brahma, Skol, Antarctica, Corona, Stella Artois) and PepsiCo non-alcoholic beverages in Brazil and Latin America, and owns Argentina's largest brewer, Quinsa. Formed in 1999 via the Brahma–Antarctica merger; combined with Canada's Labatt in 2004.

Today’s take On Aug 31, 2026 (Monday), ABEV closed at $2.87, +0.35% (+$0.01), after gapping up +1.4% to open at $2.90 (prior close $2.86, +0.01 from the Aug 28 close of $2.86 on -0.69% with 30.15M shares). Intraday range was $2.85–2.91, with the stock fading from the open to finish near the day's low. No discrete company-specific catalyst landed on this date — Q2 results were reported July 30 (organic revenue +6.1%, normalized EBITDA +8.9%, Brazil beer volumes +5.0% on FIFA World Cup demand, operating cash flow +54.5% to BRL 4.71B). The move reflects lingering post-earnings momentum plus positioning ahead of the Sept 23, 2026 ex-dividend date and the company's completed buyback (279M treasury shares cancelled Aug 12–13, BRL 3.2B program ~95% executed). Analyst sentiment stayed cautious (UBS Sell ~$2.85 target; consensus Hold/$3.34 target). The gap-up-then-fade pattern and elevated volume point to continued rebalancing/flow rather than a fresh fundamental catalyst.

Business Pfizer Inc. (NYSE: PFE) is a research-based global biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines and vaccines worldwide. Major franchises include COMIRNATY (COVID-19 vaccine), Prevnar, oncology products from the Seagen acquisition, and cardiovascular drugs such as Vyndamax and Eliquis.

Today’s take PFE closed at $28.46 on Aug 31, up $0.50 (+1.79%) from prior close of $27.96 (Aug 28), trading above its 50-day ($25.64) and 200-day ($26.10) moving averages. The primary same-day catalyst was Erste Group Bank raising its FY2026 EPS estimate to $2.96 from $2.95, near the $2.98 consensus, reinforcing a constructive analyst outlook. Supporting catalysts included the Aug 27 FDA approval of COMIRNATY XFG (2026-2027 COVID-19 vaccine for ages 65+ and high-risk ages 5-64), and the confidential Depo-Provera litigation settlement resolving ~6,200 federal cases that removed a legal overhang. Momentum from the Aug 4 Q2 earnings beat (which lifted the stock above moving averages) continued to drive buying interest. After-hours trading reached $28.50, confirming persistent demand with an average price target of $28.61.

Business Antelope Enterprise Holdings Limited (NASDAQ: AEHL) is a micro-cap holding company whose primary operations consist of two segments: a US-based natural gas power generation and energy supply business (AEHL US) serving a Texas data center and crypto-mining hosts, and a China-based livestreaming e-commerce business (Hainan Kylin). A third business-management-consulting/IT segment also generates revenue.

Today’s take AEHL closed at $6.49 on Aug 31, 2026, up +$2.95 (+83.33%), the top percentage gainer among US-listed China ADRs that session. There was no company-specific fundamental catalyst (no earnings, M&A, or contract news) on the session date. The move was a classic low-float short-squeeze/meme-style momentum event, amplified by a 1-for-16 reverse stock split effective Aug 10, 2026 that collapsed outstanding shares from 20,947,145 to roughly 1,309,197 (a ~1.1-1.3M float), drastically thinning liquidity. Intraday range was wide ($5.83-$8.48), with 46.45M shares traded against a ~377k average — roughly 120x normal volume. Trading commentary explicitly notes the surge was technically and liquidity driven rather than fundamentally anchored, following capitulation to the low-$3s then an aggressive parabolic rebound through prior sessions.

Business StablecoinX Inc. (Nasdaq: USDE) is the first publicly traded stablecoin infrastructure company focused on the Ethena digital dollar ecosystem, listed on June 26, 2026 via a SPAC merger with TLGY Acquisition Corp. It holds an ENA treasury of approximately 3.0 billion tokens (about 20% of supply, ~$218M, ~92% of its $232.6M balance sheet), making its asset value and results closely tied to Ethena's ENA governance token, which backs its USDe digital dollar products. The company also operates infrastructure services, a Harness middleware platform, and plans a Distribution Services segment with exposure to yield-bearing digital dollar products.

Today’s take USDE closed Monday Aug 31, 2026 at $8.87, up 31.21%, on 9.6M shares. The driver was the Ethena Foundation's four-part tokenomics reform announced Aug 27: an OTC buyout of locked seed-investor ENA, ending monthly VC unlocks (final on Oct 5), IP reassignment to the ENA-governed Foundation, and a fee-switch buyback vote (Aug 27–Sep 2) that would route up to 95% of net revenue into programmatic ENA buybacks once USDe supply crosses the $7.5B threshold. ENA surged double-digits (up ~10.7% in 24h and +27% on the week per Cointelegraph) over the Aug 29–31 weekend, and since StablecoinX holds ~3B ENA (~20% of supply, ~92% of its balance sheet), its equity re-rated as a direct NAV proxy tracking ENA higher. Notably the stock had extremely high volatility all August (Aug 21 +85%, Aug 27 +35%, Aug 28 -16%) reflecting speculative, momentum-driven trading in a low-float, newly-listed SPAC crypto vehicle.

Business Ticketplus Ltd. is a Cayman Islands-incorporated holding company (founded 2014, HQ in Santiago, Chile) that operates a proprietary full-stack technology platform powering live entertainment across Latin America (11 countries). It went public on NYSE American under ticker TP on August 7, 2026, priced at $8.00 per share (1,875,000 shares, ~$15M gross proceeds).

Today’s take Ticketplus rallied 30.91% to close at $10.25 on Aug 31, 2026 (intraday high $12.14, open $8.00) on volume of 538,523 shares, versus typical daily volume of ~9,000–95,000. The move coincided with IPO quiet-period expiration releasing two same-day Buy initiations: Roth Capital Partners/MKM initiated Buy with a $14 price target, and Greenridge Global (analyst William Gregozeski) initiated Buy with a $12.50 price target. The bull case was reinforced by the company's Q2 2026 results (reported ~Aug 20): revenue of $12.61M, up ~81% YoY from $6.98M, with GAAP EPS of $0.21 vs $0.10. Being a new micro-cap IPO with a thin float (1.875M shares at $8.00), the low liquidity amplified the move; NYSE American triggered an intraday volatility trading halt. The stock retreated ~26.6% from its intraday high into the close, consistent with momentum-driven low-float behavior.

Business NeoVolta Inc. (NASDAQ: NEOV) designs, manufactures, and sells energy storage systems (ESS) in the United States. Its residential products (NV14, NV24, NV16KAC) combine lithium-iron-phosphate (LFP) batteries with hybrid inverters, and the company is expanding into commercial, industrial, and utility-scale BESS through its Pendergrass, Georgia manufacturing facility.

Today’s take On Aug 31, 2026, NeoVolta surged 26.95% to close at $4.24 (range $3.82–$4.35) after its majority-owned subsidiary NeoVolta Power announced a five-year strategic supply and manufacturing collaboration with South Korea's SK On. The signed agreement covers 9 GWh of U.S.-manufactured LFP battery cells (2027–2031), with a framework to add another 9 GWh plus a pack purchase arrangement, bringing the total to ~18 GWh. Industry sources value the deal at ~$1.09 billion (1.5 trillion won), dramatically exceeding NeonVolta's trailing-12-month revenue of ~$18M. This third-party validation from a global tier-1 battery maker de-risks the Pendergrass ramp and strengthens the domestic-BESS/AI data-center narrative. The stock rose ~12% premarket to $3.75 and accelerated to the close, supported by the contract's revenue-visibility implications.

Business Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; Frankfurt: 3U8) develops, manufactures, and sells unmanned/remote data-collection platforms and quadcopter/fixed-wing drone systems across the U.S. and Canada, supported by tracking/live-stream software and training services. Founded in 1998, the company is repositioning itself as an integrated defense/security provider, winning U.S. Department of Defense contracts (DEVCOM counter-drone) and entering law-enforcement programs.

Today’s take DPRO surged +21.4% to $5.42 on Aug 31, 2026 on ~8.97M shares — roughly 8-9x the recent ~400K-500K daily average and ~6x the trailing 65-day average of ~1.45M. The primary catalyst was sector-wide drone/defense momentum: Evercore ISI initiated coverage of peer Red Cat Holdings (RCAT) with an Outperform and $15 target, citing the Pentagon's $53.6B 'Drone Dominance Program' for fiscal 2027 — the largest drone commitment in Pentagon history. This refocused attention on high-beta drone pure-plays like DPRO. Supporting triggers: (1) Aug 25 appointment of Brigadier General AJ Pasagian (USMC Ret.) as President of Draganfly Defense USA; (2) Titan Partners' Aug 19 Buy initiation with $9 target calling DPRO a 'material beneficiary' of multi-geography drone demand; (3) 6 analysts at 'Strong Buy' consensus with avg price target $10.94 (+102% upside); (4) Q2 record revenue $2.66M (+26% YoY) reported Aug 10. Short interest of ~14% of float likely contributed a short-covering element to the outsized move.

Business So-Young International Inc. (NASDAQ: SY) is China's leading online platform for consumption healthcare services, specializing in the medical aesthetics sector. Through its So-Young mobile app and branded aesthetic centers, it connects consumers with aesthetic treatment information, community content, and offline medical aesthetic services.

Today’s take So-Young surged +21.25% to a $2.91 close on Aug 31, 2026, after reporting Q2 2026 results before the market open. Total revenue rose 33.4% YoY to RMB 505.2M (US$74.5M), a quarterly record, with the aesthetic treatment services segment jumping 129.5% YoY to ~RMB 331M, beating the top of guidance by ~5%. Net loss narrowed 37% to RMB 22.7M (US$3.3M) from RMB 36.0M a year earlier, and EPS beat estimates by $0.33. The company operates 65 branded aesthetic centers (63 direct, 2 franchise) across 18 cities, with 47 centers profitable and 51 centers generating positive operating cash flow; same-store sales grew 52% YoY. Management guided Q3 2026 aesthetic treatment services revenue to RMB 352-362M (+91.7-97.2% YoY), signaling continued acceleration. The print came after So-Young appointed former Gaotu Techedu CFO Nan Shen as CFO effective Aug 3, a governance/efficiency signal that preceded the bullish drift into earnings.

Business UTime Limited (Nasdaq: FXHO, formerly WTO) is a Shenzhen, China-based developer and manufacturer of mobile phones, accessories, and consumer electronics, also providing EMS (OEM/ODM) services. The company markets under the UTime and Do brand names and is exploring Web3/digital infrastructure expansion.

Today’s take FXHO closed at $12.32 on Aug 31, 2026, +18.69% (+$1.94) from the Aug 28 close of $10.38, extending a highly volatile pattern that characterized the stock all summer. No company-specific announcement was made on Aug 31 itself; the move reflects continued speculative momentum in this low-float Chinese micro-cap riding the Feixiaohao Web3/crypto acquisition narrative (non-binding LOI signed March 2026). Recent context: FY2026 results (Aug 10) showed revenue down 22% YoY to CNY196M with narrowed losses, and the stock saw multiple ±15-34% daily swings through July-August, including a +171.5% move on Jul 6 with 8.1M shares traded. The stock also underwent a 10-for-1 reverse split (June) and ticker change WTO→FXHO (July 2). Volume on Aug 31 was ~157K shares, below the August peak of 1M+, suggesting the rally was driven more by order-flow imbalance than heavy institutional accumulation. The pattern is classic speculative micro-cap momentum.

Business Evolution Metals & Technologies Corp. (EMAT) is a NASDAQ-listed critical materials and rare earth magnet company. It produces rare earth magnet products and battery metals, operating a rare earth magnet plant in Pohang, South Korea, with expansion from 1,000 to 10,000 metric tons of annual magnet capacity. The company is building a non-China rare earth supply chain (NdPr from Vietnam) to serve defense-compliant magnet demand ahead of the January 1, 2027 DFARS deadline. On August 27, 2026, EMAT announced an agreement with Korea Electric Power Corp. (KEPCO) to expand Pohang power infrastructure from 130 MW to 750 MW, supporting a facility expansion to 482,000 sq ft and tenfold production. The company was preliminarily added to the Russell 3000 and Russell 2000 indexes effective September 21,

Today’s take On August 31, 2026 (Monday), EMAT closed at $3.86, up $0.59 (+18.20%), on volume of 1,310,911 shares — roughly 3.3x the ~392K daily average. The session was extremely volatile: open 3.25, high 3.98, low 3.03, reversing from a weak/pre-market start to close near the highs. No single fresh company-specific headline fired on Aug 31 itself. Rather, the +18% move was a sharp high-volatility technical rebound within an ongoing fundamental re-rating narrative. In the prior week the stock had surged on preliminary Russell 3000/2000 inclusion (announced Aug 24, effective Sept 21), then sold off sharply Aug 25-28 (down 6.4%, 14.7%, 5.6%) on profit-taking and dilution fears over the $100M Yorkville financing facility ($20M principal outstanding, with $5.775M already converted) and weak Q2 revenue highlighting tight liquidity. The KEPCO Pohang 750 MW expansion news (Aug 27) reinforced the growth narrative. On Aug 31, the stock rebounded hard from oversold levels as 'buy-the-dip' traders and short covering (short sale ratio ~33%) re-entered ahead of the confirmed Russell index addition, with index-fund buying flows expected effective Sept 21. The move was a classic volatile reversal/rebound day

Business Valion Bio, Inc. (NASDAQ: VBIO; formerly Tivic Health Systems, renamed April 2026) is a late-stage biopharmaceutical company headquartered in San Antonio, Texas. Its lead candidate Entolimod, a TLR5 agonist, is in late-stage development to treat Acute Radiation Syndrome, alongside pipeline assets Entolimod (neutropenia/lymphocyte exhaustion) and Entolasta, plus CDMO services via wholly owned Velocity Bioworks.

Today’s take The Aug 31, 2026 session catalyst was the reverse stock split that took effect at 12:01 AM ET that day. Announced Aug 27, 2026 and approved at the Aug 14 shareholder meeting (which authorized a ratio between 1-for-5 and 1-for-50), the consolidation was executed to regain compliance with Nasdaq's minimum bid price rule, which the company had until Sept 15, 2026 to satisfy. Sources disagree on the implemented ratio: RTTNews reports 1-for-20 while Accesswire/Barchart/TheFly and the split-adjusted data report 1-for-25. Trading was halted 'news pending' ahead of the effective date. VBIO opened at $2.80, traded to a high of $3.87, and closed at $3.57, up $0.55 (+18.11%) on roughly 622K-660K shares. The on-session gain is largely a mechanical result of the share-count consolidation raising the per-share price, not fundamental news. Context: the stock was down roughly 90% YTD and ~95% over 12 months, having spiked and pulled back in July-August on reverse-split speculation.

Business General Fusion Group Ltd. (NASDAQ: GFUZ) is a Vancouver, Canada-based clean energy company pursuing commercial fusion energy using its Magnetized Target Fusion (MTF) technology. It became the first publicly listed fusion company after completing a business combination with Spring Valley Acquisition Corp. III, beginning trading on Nasdaq on July 13, 2026.

Today’s take GFUZ closed at $8.10 on Aug 31, 2026, up $1.07 (+15.22%), the largest one-day gain since its July 13 de-SPAC listing. Actual traded volume reached ~513,000-515,000 shares (opening $7.17, ranging $7.17-$8.53), roughly 3-4x the ~120,000-210,000 average over the prior two weeks (the prompt's 'Volume: 0' reflects a WSJ data feed quirk). No discrete company press release occurred on Aug 31 itself; the move was driven by a high-beta repositioning of this low-float, newly-listed fusion pure-play, building on the Aug 18 first-public-company business update (LM26 plasma heated to 0.72 keV, ~US$150M cash runway) and the bullish Aug 28-30 energyreporter.news feature framing GFUZ around surging AI/data-center power demand and the fusion thematic. After-hours drifted to $7.90 (-2.47%), paring gains. Market cap ~$516M at close.

Business CID HoldCo, Inc. (NASDAQ: DAIC), doing business as Dot Ai, is a micro-cap IoT and AI-based SaaS company providing Asset Intelligence for smart supply-chain operations. It delivers real-time asset-tracking and predictive-analytics platforms built on RFID, AI edge-camera, 5G RF/BLE technology, serving aviation, construction, military, mining, retail, seaports, warehousing and manufacturing.

Today’s take DAIC fell -25% to close at $3.48 on Aug 31, 2026 (open $3.84, high $4.08, low $3.46), extending a massive speculative unwind. The stock had exploded from ~$0.43 on Aug 21 to a peak of $6.69 intraday on Aug 26 amid a meme-style retail rally described by Yahoo Business as having no identifiable fundamental catalyst. After peaking, shares fell -19.44% on Aug 28 to $4.64 and another -25% on Aug 31, with no company-specific news on the session. The rally rode on a tiny float of ~692K shares (12.95% short interest) after Nasdaq issued a delisting Staff Determination (Aug 6) for failure to meet the $50M MVLS requirement, a 1-for-25 reverse split (June 1), and a strategic-alternatives review. The Aug 31 decline was pure momentum reversal/profit-taking as the speculative bid evaporated.

Business Z Squared Inc. (NASDAQ: ZSQR), formerly Coeptis Therapeutics Holdings, is a digital infrastructure and computing company that operates approximately 9,800 Scrypt-algorithm ASIC mining machines across six facilities in North Carolina, South Carolina, and Iowa, generating revenue through Dogecoin (88%) and Litecoin (12%) mining. The company is expanding into AI data center infrastructure.

Today’s take ZSQR plunged 23.58% on August 31, 2026, closing at $2.95 after opening at $3.86, as a broad crypto selloff hit the pure-play Dogecoin/Litecoin miner. Bitcoin broke below $77,000 intraday (to $76,996) on renewed US-Iran military strikes and hawkish Fed Chair Kevin Warsh's Jackson Hole comments, triggering over $200M in crypto liquidations in one hour. Dogecoin, which represents ~88% of ZSQR's revenue, fell 2.48% to ~$0.082. The decline was compounded by structural overhangs: a 41.58M share resale registration (~80% of float), a $13.72M net loss on just $1.58M revenue in Q2 2026 (first post-reverse-merger quarter), and the all-stock Paradox Data acquisition ($5M Series A Preferred convertible at $7.45/share). The stock had already fallen from ~$5.29 on July 29 to $3.86 by Aug 28, with Aug 31 marking an acceleration.

Business Edison International (NYSE: EIX), headquartered in Rosemead, California, is a holding company whose principal subsidiary is Southern California Edison (SCE), one of the largest U.S. electric utilities. SCE generates and distributes electricity to roughly 5 million customers across a ~50,000-square-mile service area in southern, central, and coastal California. The company also holds interests in nonutility energy products and services through its Edison Energy unit.

Today’s take EIX cratered -23.07% on Aug 31, 2026, closing at $53.98 (from $70.17) — its worst single-day decline in over 25 years. The trigger was California's SB 492 passing without a $6 billion per-incident liability cap or Wildfire Fund replenishment mechanism, denying utilities the financial protections Wall Street had priced in. Gov. Newsom's proposal to shield utilities from insurer subrogation lawsuits over wildfire damages collapsed over the weekend. Mizuho downgraded EIX to Neutral from Outperform, cutting its target from $86 to $70, explicitly citing the reform failure. Peer PG&E (PCG) tumbled ~18-20% and Sempra (SRE) fell ~3% the same session, confirming a sector-wide regulatory de-rating. Notably, just weeks earlier (Aug 11) EIX had rallied +3.04% on a favorable tentative court ruling in SCE's Eaton wildfire case; the Aug 31 crash reversed that relief rally. Volume surged to ~24.6 million shares (~6-10x normal), reflecting panic institutional de-risking.

Business YD Bio Limited (NASDAQ: YDES) is a Taiwan-headquartered (Cayman Islands-registered) public biotechnology company building an integrated healthcare platform spanning DNA methylation-based early cancer detection diagnostics (OkaiDx), stem cell and exosome-based regenerative therapeutics, and clinical/commercial lab services. With ~70.3M shares outstanding and a small ~$510K TTM revenue base, it remains a pre-commercial biotech facing persistent operating losses.

Today’s take YD Bio fell -22.71% to $3.71 on Aug 31, 2026, after releasing same-day unaudited H1 FY26 (six months ended June 30, 2026) results via GlobeNewswire. Revenues rose 315% to $846,501, yet the company reported a $6.7M net income largely inflated by a $9.85M non-cash change in fair value of warrant liabilities, while operating loss actually WIDENED 66% to $3.23M. The critical red flag: cash plunged to just $2.66M at June 30, 2026, from $6.01M at Dec 31, 2025 — a severe liquidity crunch for a capital-intensive biotech developing DNA-methylation cancer diagnostics with minimal revenue. Markets interpreted this as signaling a near-term, highly dilutive capital raise. Compounding the selloff, the stock had run up ~+109% in the prior three weeks (from ~$2.30 on Aug 7 to $4.80 on Aug 28, +24% on Aug 28 alone), so the earnings triggered substantial profit-taking. Volume hit 445,203 shares, roughly 12-20x the ~11K-35K typical daily volume of the preceding week, marking a decisive distribution day.

Business Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee, listed on NASDAQ (CPIX). After completing its strategic transaction with Apotex Health Corp. ($100M cash for its FDA-approved product line), Cumberland transitioned into a development-stage biopharma focused on advancing late-stage pipeline candidates, including ifetroban in Duchenne Muscular Dystrophy (DMD), Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.

Today’s take CPIX plunged 20.92% to close at $6.69 on Aug 31, 2026 (open 8.21, low 6.58, volume 188,295, roughly 4x the prior day's 45,179). The catalyst was clinical: on Aug 27, 2026 Cumberland corrected guidance and disclosed that the Phase 2 FIGHT DMD open-label extension long-term safety/efficacy data — widely expected to be presented in August 2026 per a PPMD conference slide — were NOT yet available, pulling the August presentation timing. On Aug 29 an 8-K surfaced that Cumberland was seeking FDA action on the ifetroban DMD data before the extension study is complete. The stock had run up from ~$4.65 in January to an all-time-high $9.28 on Aug 26, 2026 on the Apotex deal, the $1.50 special dividend ($22M), and ifetroban optimism. It slipped -3.57% (Aug 27) and -2.20% (Aug 28) before capitulating -20.92% on Aug 31 when it became clear the key near-term August data milestone would not materialize.

Business PG&E Corporation is a public utility holding company headquartered in Oakland, California, operating on the NYSE under ticker PCG. Through its wholly owned subsidiary Pacific Gas and Electric Company, it generates, transmits, and distributes electricity and provides natural gas service to approximately 5.3 million electricity and 4.6 million natural gas customers across 47 of California's 58 counties, with power sourced from nuclear, hydroelectric, fossil-fuel, and renewable generation.

Today’s take On Monday August 31, 2026, PCG plunged -20.06% to close at $13.27, its worst single-day drop since March 18, 2020, on 152.96M shares (roughly 3.3x its ~46M average volume). The collapse followed California's State Assembly amending Senate Bill 492 to strip out wildfire-liability protections that investors expected — leaving utilities exposed to uncapped, open-ended wildfire liabilities beyond 2030. PG&E on Sunday (8/30) said SB 492 'falls short of long-term wildfire reform' and does not address financing risks of the state's wildfire liability framework. The legislative setback triggered immediate downgrades: Mizuho cut PCG to Neutral from Outperform (PT $21→$16), BMO Capital to Market Perform from Outperform (PT $28→$21), and Wells Fargo to Equal Weight from Overweight. Sector contagion hit Edison International (EIX) and Sempra (SRE) as Mizuho downgraded all three California utilities. The stock erased its year-to-date gains built on hopes the Newsom-backed liability shift would pass.

Business Cre8 Enterprise Limited (NASDAQ: CRE) is a Hong Kong-based integrated financial printing service provider offering 24/7 services to listed companies, IPO applicants, and private firms, including typesetting, translation, printing, e-submissions, and IR-related tech support under its Cre8 and Cre8IR brands.

Today’s take CRE fell -19.18% to $3.16 on Aug 31, 2026 on ~127K shares, continuing the third consecutive unwinding session after an explosive short-squeeze-style rally. On Aug 26, the company reported a record 550 customers served and record project backlog as of June 30, 2026, triggering a +164.98% single-day spike to $6.81 on a staggering 64.2M shares (vs. typical daily volume of just ~5–30K). The stock then gave back gains: -13.36% on Aug 27 ($5.90, 1.24M sh), -33.73% on Aug 28 ($3.91, 321K sh), and -19.18% on Aug 31 ($3.16). No fresh company-specific news was issued on Aug 31 itself. CRE is a micro-cap (market cap ~$5-8M) with a tiny ~1.1M public float, ~69.7K short shares (6.34% of float, 0.06 days-to-cover), and underwent a 1-for-12 reverse split on Feb 13, 2026 to regain Nasdaq's $1 bid compliance. The decline reflects post-spike profit-taking and speculative froth deflation rather than a new fundamental catalyst.

Business Exascale Labs Holdings Inc. (NASDAQ: XLAB) is a next-generation AI infrastructure provider operating an asset-light, software-defined GPU compute platform. Its core business is GPU-as-a-Service (GaaS), providing reserved and on-demand access to high-performance GPU compute capacity sourced from third-party data centers, plus GPU cluster management and optimization services.

Today’s take XLAB fell 18.68% on Aug 31, 2026, closing at $4.18 after opening at $4.58 (range $4.01-$4.62), continuing a steep post-SPAC unwind. The stock began trading on Nasdaq as XLAB after the SPAC merger with D. Boral ARC Acquisition I Corp. closed following shareholder approval on July 29, 2026. On Aug 28, the stock spiked 5.7M shares (opening $6.20, high $7.39), before collapsing 18.68% by Monday Aug 31. That same day, at 2:00 PM ET, the company announced a non-binding MOU with EnergyBank to develop grid-independent AI compute powered by floating offshore wind and long-duration storage (pilot up to 800 kW on Zephyros-One turbine, targeting up to 10 MW per turbine). The MOU did not arrest the decline, which reflects heavy SPAC trust redemptions leaving only ~$12M, thin liquidity, and profit-taking after the Aug 28 speculative volume spike. Volume on Aug 31 was 276,700 shares, elevated vs. typical daily flow but modest vs. the 5.7M Aug 28 surge, indicating momentum unwinding rather than a fresh fundamental shock.

Business Aethlon Medical, Inc. (Nasdaq: AEMD), incorporated in Nevada and headquartered in San Diego, CA, is a clinical-stage medical-therapeutics company developing the Hemopurifier, an investigational extracorporeal blood-purification device designed to remove harmful substances including extracellular vesicles and enveloped viruses from blood, targeting oncology, life-threatening infectious disease, and organ transplantation. The device holds two FDA Breakthrough Device Designations.

Today’s take On Aug 31, 2026, AEMD closed at $2.06, down 17.27% from $2.49, in a sharp reversal after a massive prior-session surge. The primary catalyst was an 8-K filed Aug 31 disclosing that all remaining pre-funded warrants had been exercised, bringing outstanding common shares to 1,604,095 as of the Aug 28 close — explicit dilution pressure. This followed Aug 28's extraordinary +14.75% jump on ~44.6M shares (vs typical ~30-150K daily), a speculative spike driven by the narrowed Q1 FY2027 loss (net loss -$1.55M, -$4.02/share, down from -$1.76M) reported Aug 13 and the Nasdaq 'narrower loss, stock jumps' headline. The Aug 31 session (opened $2.29, low $1.92, vol ~838K) reflected profit-taking/reversal after the run-up, amplified by the warrant-exercise dilution disclosure. The stock trades around $2 post a 1-for-5 reverse split effected July 31, 2026, with earnings per share heavily affected by share-count changes.

Business Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company listed on Nasdaq (TECX) that discovers and develops therapeutic proteins and antibodies that modulate G protein-coupled receptors (GPCRs) using its proprietary GEODe platform. Its lead candidate TX45 is an Fc-relaxin fusion protein targeting RXFP1 in Phase 2 trials for Group 2/3 pulmonary hypertension, along with early-stage candidate TX2100 for hereditary hemorrhagic telangiectasia.

Today’s take On 8/31/2026, TECX tumbled ~15.95% to $29.94 on ~718,893 shares (~3.7x its ~194K average volume) with no company-specific catalyst. Financial Modeling Prep's same-day market wrap states: "No clear same-day company announcement fully explains the decline," attributing the move to general biotech volatility. The stock had entered the session in a deep multi-week uptrend — from ~$20 in Feb to a ~$38 peak on Aug 27 (driven by positive TX45 Phase 1b data in Oct 2025 plus mid-Aug surge: +15.56% on 8/12, +8.15% on 8/18). Short interest was elevated at ~20.4% of float (1.94M shares, ~9.3 DTC) as of 7/15/26, amplifying downside. The most recent operational update (8/6 Q2 results — completed TX45 APEX enrollment and TX2100 Ph1a single-dose cohorts) was ~3.5 weeks earlier, so this sharp pullback with ~3x volume is best characterized as profit-taking/unwinding of a parabolic move and high-beta biotech sector volatility in a heavily-shorted name, rather than a fundamental deterioration. TX45 APEX topline is expected late Q4 2026/early Q1 2027; TX2100 Ph1a data by end-Q3 2026.